Heart failure (HF) is a complex clinical syndrome caused by a wide range of cardiovascular disorders (such as structural or functional abnormalities of the heart) and represent the main cause of mortality and poor quality of life in the western societies. According to the European Heart Failure Association, 26 million people experience HF globally and 3.6 million people are diagnosed with HF, every year. Nowadays, the common clinical approaches used to diagnose and monitor HF are based on analyzing natriuretic peptides (e.g. B-type or N-terminal pro-B-type natriuretic peptides) in serum and performing transthoracic Doppler 2D echocardiography. Beside these conventional clinical investigations, breath analysis is an extraordinarily appealing tool for a most effective, easy, painless and non-invasive monitoring of patients suffering from HF because of the chemical composition of exhaled breath reflects the physiological and pathophysiological process. The aim of this work was to develop an analytical procedure, based on Needle Trap Micro-Extraction coupled to GC-MS/MS, to determine volatile organic compounds (VOCs) in human breath. This emerging and promising technique that employ a stainless-steel needle (internal diameter 0.34 mm and length 6 cm) packed with 1 cm of Divinylbenzene, 1 cm of Carbopack X and 1 cm of Carboxen 1000 allows analytes sampling and-pre-concentration to be performed in a single step. Needle trap devices were automatically desorbed by a CONCEPT GC-autosampler (PAS Technology) and VOCs were analysed by a 7890B GC System equipped with a DB5ms gas chromatographic column (60 m, 0.25 mm ID, 1.0 μm) and coupled to a 7010 MS Triple Quad mass spectrometer (Agilent Technologies). The method was then used in the framework of the H2020 HEARTEN project to support the development of specific biosensors (e.g. acetone), which will be integrated into an innovative mobile platform remotely connected by an mHealth application. According to this scenario, HF patients will be able to monitor itself at home by using their smartphones.
Determination of volatile organic compounds in human breath for monitoring heart failure patients
Tommaso Lomonaco;Silvia Ghimenti;Francesca Bellagambi;Denise Biagini;Valentina Barletta;Andreina D’Agostino;Doralisa Morrone;Mario Marzilli;Maria Giovanna Trivella;Fabio Di Francesco;Roger Fuoco
2017-01-01
Abstract
Heart failure (HF) is a complex clinical syndrome caused by a wide range of cardiovascular disorders (such as structural or functional abnormalities of the heart) and represent the main cause of mortality and poor quality of life in the western societies. According to the European Heart Failure Association, 26 million people experience HF globally and 3.6 million people are diagnosed with HF, every year. Nowadays, the common clinical approaches used to diagnose and monitor HF are based on analyzing natriuretic peptides (e.g. B-type or N-terminal pro-B-type natriuretic peptides) in serum and performing transthoracic Doppler 2D echocardiography. Beside these conventional clinical investigations, breath analysis is an extraordinarily appealing tool for a most effective, easy, painless and non-invasive monitoring of patients suffering from HF because of the chemical composition of exhaled breath reflects the physiological and pathophysiological process. The aim of this work was to develop an analytical procedure, based on Needle Trap Micro-Extraction coupled to GC-MS/MS, to determine volatile organic compounds (VOCs) in human breath. This emerging and promising technique that employ a stainless-steel needle (internal diameter 0.34 mm and length 6 cm) packed with 1 cm of Divinylbenzene, 1 cm of Carbopack X and 1 cm of Carboxen 1000 allows analytes sampling and-pre-concentration to be performed in a single step. Needle trap devices were automatically desorbed by a CONCEPT GC-autosampler (PAS Technology) and VOCs were analysed by a 7890B GC System equipped with a DB5ms gas chromatographic column (60 m, 0.25 mm ID, 1.0 μm) and coupled to a 7010 MS Triple Quad mass spectrometer (Agilent Technologies). The method was then used in the framework of the H2020 HEARTEN project to support the development of specific biosensors (e.g. acetone), which will be integrated into an innovative mobile platform remotely connected by an mHealth application. According to this scenario, HF patients will be able to monitor itself at home by using their smartphones.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
